This study focuses on testing a new medication called IMG-007 for people who have moderate-to-severe atopic dermatitis, which is a chronic skin condition causing red, itchy, and inflamed skin. The medication is given as a subcutaneous injection under the skin.
The purpose of this research is to evaluate how well different doses of IMG-007 work compared to placebo in treating atopic dermatitis. The study will examine if the medication can reduce the severity and extent of skin symptoms in adults with this condition. The medication will be tested over a period of 20 weeks to determine its effectiveness and safety.
During the study, participants will receive either IMG-007 or placebo through injections under the skin. The study is designed as a double-blinded trial, which means neither the participants nor the doctors conducting the study will know who receives the actual medication and who receives the placebo. Participants will be allowed to continue using regular moisturizers throughout the study period.
Czechia 
Germany 
Hungary 
Poland 
Spain 
